CLINICAL TRIALS PROFILE FOR PROTAMINE SULFATE

All Clinical Trials for Protamine Sulfate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00684450 ↗	Cardiac Surgery: In Vivo Titration of Protamine	Completed	Organon	N/A	2008-06-01	Safe use of cardiopulmonary bypass (CPB) requires massive doses of intravenous unfractionated heparin. At end-CPB, residual heparin is neutralized with intravenous injection of protamine sulfate. This prospective, randomized, controlled study will be conducted in 82 voluntary subjects admitted for elective, first intention, cardiac surgery requiring cardiopulmonary bypass. Each will be randomly assigned to one of two groups. The control group will be submitted to a standard protamine infusion of 1.3mg :100U of the total heparin dose given during bypass. The test group will receive an infusion of protamine (over 15 minutes) until activated clotting time (ACT) values (determined every 3 minutes) depict a plateau, sign that the optimal protamine to heparin ratio has been attained. The investigators hypothesize this new in vivo titration method to be as efficient as the standard protocol (adequacy of heparin neutralization, % heparin rebound, bleeding, and transfusion), and potentially safer by its ability to prevent protamine overdose and its deleterious impact on platelet function.15 Principal Objective Evaluate a new in vivo method of titration of protamine sulfate. Secondary Objective Evaluate the impact of this method on the adequacy of heparin neutralization by measuring: 1. platelet count 2. postoperative bleeding 3. transfusion exposure a 4. incidence of heparin rebound
NCT00684450 ↗	Cardiac Surgery: In Vivo Titration of Protamine	Completed	Montreal Heart Institute	N/A	2008-06-01	Safe use of cardiopulmonary bypass (CPB) requires massive doses of intravenous unfractionated heparin. At end-CPB, residual heparin is neutralized with intravenous injection of protamine sulfate. This prospective, randomized, controlled study will be conducted in 82 voluntary subjects admitted for elective, first intention, cardiac surgery requiring cardiopulmonary bypass. Each will be randomly assigned to one of two groups. The control group will be submitted to a standard protamine infusion of 1.3mg :100U of the total heparin dose given during bypass. The test group will receive an infusion of protamine (over 15 minutes) until activated clotting time (ACT) values (determined every 3 minutes) depict a plateau, sign that the optimal protamine to heparin ratio has been attained. The investigators hypothesize this new in vivo titration method to be as efficient as the standard protocol (adequacy of heparin neutralization, % heparin rebound, bleeding, and transfusion), and potentially safer by its ability to prevent protamine overdose and its deleterious impact on platelet function.15 Principal Objective Evaluate a new in vivo method of titration of protamine sulfate. Secondary Objective Evaluate the impact of this method on the adequacy of heparin neutralization by measuring: 1. platelet count 2. postoperative bleeding 3. transfusion exposure a 4. incidence of heparin rebound
NCT01006863 ↗	Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study	Completed	Mansoura University	Phase 2	2004-03-01	The prophylactic use of small doses of ephedrine may be effective in obtunding of the hypotension responses to propofol with minimal hemodynamic and ST segment changes. The investigators aimed to evaluate the effects of small doses of ephedrine on hemodynamic responses of propofol anesthesia for valve surgery. There is widespread interest in the use of propofol for the induction and maintenance of anesthesia for fast track cardiac surgery. However, its use for induction of anesthesia is often associated with a significant rate related transient hypotension for 5-10 minutes. This is mainly mediated with decrease in sympathetic activity with minor contribution of its direct vascular smooth muscle relaxation and direct negative inotropic effects. Ephedrine has demonstrated as a vasopressor drug for the treatment of hypotension in association with spinal and general anesthesia. Prophylactic use of high doses of ephedrine [10-30 mg] was effective in obtunding the hypotensive response to propofol with associated marked tachycardia. However, the use of smaller doses (0.1-0.2 mg/kg) was successfully attenuated, but not abolished, the decrease in blood pressure with transient increase in heart rate. This vasopressor effect is mostly mediated by β-stimulation rather than α-stimulation and also indirectly by releasing endogenous norepinephrine from sympathetic nerves. Because the effect of decreasing the dose of ephedrine from 0.1 to 0.07 mg/kg may be clinically insignificant, the investigators postulated that the prophylactic use of small dose of ephedrine may prevent propofol-induced hypotension after induction of anesthesia for valve surgery with minimal in hemodynamic, ST segment, and troponin I changes. The aim of the present study was to investigate the effects of pre-induction administration of 0.07, 0.1, 0.15 mg/kg of ephedrine on heart rate (HR), mean arterial blood pressure (MAP), central venous and pulmonary artery occlusion pressures (CVP and PAOP, respectively), cardiac (CI), stroke volume (SVI), systemic and pulmonary vascular resistance (SVRI and PVRI, respectively), left and right ventricular stroke work (LVSWI and RVSWI, respectively) indices, ST segment, and cardiac troponin I (cTnI) changes in the patients anesthetized with propofol-fentanyl for valve surgery.
NCT01006863 ↗	Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study	Completed	King Faisal University	Phase 2	2004-03-01	The prophylactic use of small doses of ephedrine may be effective in obtunding of the hypotension responses to propofol with minimal hemodynamic and ST segment changes. The investigators aimed to evaluate the effects of small doses of ephedrine on hemodynamic responses of propofol anesthesia for valve surgery. There is widespread interest in the use of propofol for the induction and maintenance of anesthesia for fast track cardiac surgery. However, its use for induction of anesthesia is often associated with a significant rate related transient hypotension for 5-10 minutes. This is mainly mediated with decrease in sympathetic activity with minor contribution of its direct vascular smooth muscle relaxation and direct negative inotropic effects. Ephedrine has demonstrated as a vasopressor drug for the treatment of hypotension in association with spinal and general anesthesia. Prophylactic use of high doses of ephedrine [10-30 mg] was effective in obtunding the hypotensive response to propofol with associated marked tachycardia. However, the use of smaller doses (0.1-0.2 mg/kg) was successfully attenuated, but not abolished, the decrease in blood pressure with transient increase in heart rate. This vasopressor effect is mostly mediated by β-stimulation rather than α-stimulation and also indirectly by releasing endogenous norepinephrine from sympathetic nerves. Because the effect of decreasing the dose of ephedrine from 0.1 to 0.07 mg/kg may be clinically insignificant, the investigators postulated that the prophylactic use of small dose of ephedrine may prevent propofol-induced hypotension after induction of anesthesia for valve surgery with minimal in hemodynamic, ST segment, and troponin I changes. The aim of the present study was to investigate the effects of pre-induction administration of 0.07, 0.1, 0.15 mg/kg of ephedrine on heart rate (HR), mean arterial blood pressure (MAP), central venous and pulmonary artery occlusion pressures (CVP and PAOP, respectively), cardiac (CI), stroke volume (SVI), systemic and pulmonary vascular resistance (SVRI and PVRI, respectively), left and right ventricular stroke work (LVSWI and RVSWI, respectively) indices, ST segment, and cardiac troponin I (cTnI) changes in the patients anesthetized with propofol-fentanyl for valve surgery.
NCT02033629 ↗	Low Remifentanil Target Controlled Infusions for Cardiac Surgery	Completed	Dammam University	Phase 3	2014-05-01	The development of target effect-site controlled concentrations (TCI) of remifentanil have gained increasing acceptance during cardiac surgery as regarding the resulting of hemodynamic stability and early extubation. The use of low-dose opioid technique has been progressively used nowadays because of its ceiling effect to attenuate cardiovascular responses to noxious stimuli. We hypothesize that the use of low target remifentanil effect site concentrations may provide comparable shorter times to tracheal extubation and hemodynamic stability to the use of high remifentanil Ce during target-controlled propofol anesthesia for cardiac surgery.
NCT02974660 ↗	Protamine Sulfate During Transcatheter Aortic Valve Implantation	Completed	Medical University of Warsaw	Phase 4	2016-12-01	Transcatheter aortic valve implantation (TAVI) is a new, rapidly emerging standard of care in inoperable and high-risk patients with severe, symptomatic aortic stenosis. Information regarding reversal of unfractionated heparin with protamine sulfate in order to facilitate access site closure is scarce and based on expert consensus. Clinical practice varies between centers. Protamine sulphate may decrease the amount of bleeding complications related to the access-site. The impact on possible thromboembolic complications is unknown. Both bleeding and thromboembolic complications increase mortality after TAVI. A randomized trial is required in order to assess impact of protamine sulfate on prevalence and extent of bleeding and thromboembolic complications.

Clinical Trial Conditions for Protamine Sulfate

Condition Name

Condition Name for Protamine Sulfate
Intervention	Trials
Aortic Valve Stenosis	3
Acute Kidney Injury	2
Bleeding	2
Blood Transfusion Complication	1

Condition MeSH

Condition MeSH for Protamine Sulfate
Intervention	Trials
Aortic Valve Stenosis	3
Acute Kidney Injury	2
End Stage Liver Disease	1
Delirium	1

Clinical Trial Locations for Protamine Sulfate

Trials by Country

Trials by Country for Protamine Sulfate
Location	Trials
Egypt	8
Netherlands	3
Canada	2
Saudi Arabia	2
Jordan	1

Trials by US State

Trials by US State for Protamine Sulfate
Location	Trials
Michigan	1

Clinical Trial Progress for Protamine Sulfate

Clinical Trial Phase

Clinical Trial Phase for Protamine Sulfate
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Protamine Sulfate
Clinical Trial Phase	Trials
Completed	13
RECRUITING	3
Unknown status	2

Clinical Trial Sponsors for Protamine Sulfate

Sponsor Name

Sponsor Name for Protamine Sulfate
Sponsor	Trials
Ain Shams University	4
Fayoum University Hospital	2
University of Novi Sad	1

Sponsor Type

Sponsor Type for Protamine Sulfate
Sponsor	Trials
Other	23
Industry	1

Protamine Sulfate: Clinical Trials Update, Market Analysis, and 2025-2035 Projection

Last updated: April 30, 2026

Where is protamine sulfate in the clinical pipeline?

Protamine sulfate is a long-established drug used to reverse heparin anticoagulation and to reduce protamine-related adverse reactions in procedural settings. Public clinical-development activity is not centered on brand-new drug entities; it is concentrated in (1) dosing/regimen optimization, (2) route/formulation refinement, (3) perioperative safety, and (4) use in broader anticoagulation contexts.

What do the most recent clinical and regulatory signals indicate?

Across the last several years, the dominant pattern for protamine sulfate studies has been:

• Heparin reversal efficacy and safety in cardiac surgery, extracorporeal circulation, and interventional procedures.
• Risk reduction for protamine hypersensitivity (including strategies to mitigate acute reactions).
• Comparative performance among protamine sources, concentrations, and delivery protocols.
• Downstream outcomes such as bleeding reduction, transfusion use, and perioperative hemodynamic stability.

Clinical endpoint themes reported in the protamine sulfate literature are consistent: time-to-anticoagulation reversal, thrombin activity parameters, activated clotting time (ACT) kinetics, bleeding rates, and adverse event incidence focused on hypotension, anaphylactoid reactions, and respiratory compromise.

Trial types commonly used for protamine sulfate in practice

• Prospective perioperative observational trials (real-world protocols and safety surveillance)
• Pharmacodynamic studies (ACT and coagulation factor activity endpoints)
• Comparative dosing/regimen studies (total dose caps, incremental bolusing)
• Safety-focused studies targeting hypersensitivity prevention

Source basis: The protamine sulfate use case and reversal mechanism are documented in core drug references and clinical guidance, including the heparin-antidote role and hypersensitivity risk characterization. [1-3]

---

What is the commercial market context for protamine sulfate?

Market drivers

• Perioperative heparin use: Protamine sulfate demand tracks procedures with systemic heparin exposure, especially cardiac surgery and extracorporeal circuits.
• Anticoagulation reversal requirement: Standards of care generally require reversal or neutralization after high-dose heparin.
• Manufacturing scalability and generics: Protamine sulfate is structurally simple but produces value via reliable supply, dosing accuracy, and acceptable safety profiles.

Market constraints

• Hypersensitivity risk: Acute protamine reactions constrain adoption patterns and increase pharmacovigilance burden.
• Generics and price pressure: In established markets, patent expiry and multiple sources compress margins.
• Usage is tied to specific procedures: Growth follows procedure volumes more than chronic disease prevalence.

---

How big is the protamine sulfate market and how does it grow?

Public market sizing for protamine sulfate is not consistently reported at high granularity across paid industry sources. The most defensible sizing framework uses procedure-volume linkage: heparin anticoagulation demand in cardiac surgery and extracorporeal circuits, plus additional uses in other interventional settings where reversal is routine.

Projection framework used for this forecast

1. Procedure demand base (cardiac surgery and related extracorporeal procedures)
2. Conversion factor (share of procedures using protamine, influenced by protocol adoption)
3. Dose intensity and dosing conservative caps (average protamine utilization per case)
4. Unit economics (generic pricing bands, reimbursement dynamics, and procurement cycles)

2025-2035 projection (value and volume)

Given the typical generic landscape for protamine sulfate and stable clinical utility, the most likely outcome is low-to-mid single-digit annual growth in value with more stable volume growth driven by procedure volumes and substitution within generics.

Base-case outlook (2025-2035):

• Volume (units/packs/liquid equivalents): low single-digit CAGR, primarily procedure-volume driven.
• Value (revenue): mid-to-high single-digit CAGR early in the window depending on price stabilization after procurement swings, then moderates as competition persists.

This pattern is consistent with established, guideline-supported antidote drugs where clinical need is stable but pricing is competitive.

---

What competitive dynamics shape protamine sulfate pricing?

Pricing pressure is structurally linked to:

• Multisource generic supply: multiple manufacturers compete on cost.
• Hospital formulary switching: procurement favors reliable supply and lowest-cost acquisition when safety profiles are acceptable.
• Standardization of protocols: dosing tables and ACT targets are codified, limiting differentiation.

Differentiation that still matters commercially

• Stability and concentration consistency (dose accuracy and shelf-life)
• Manufacturing continuity (avoid shortages and production discontinuities)
• Safety record in perioperative settings (reactogenicity management and labeling)

---

What are the commercial “hot zones” for demand growth?

Demand tends to strengthen in settings with higher heparin procedural intensity:

• Cardiac surgery volume (CABG, valve surgery, and associated extracorporeal circulation)
• Expansion of minimally invasive cardiothoracic workflows (some protocols use adjusted heparin dosing and reversal patterns)
• Geographic growth where procedure volumes expand faster than mature markets
• Hospital networks that standardize reversal protocols and reduce dosing variability

---

What investment and R&D implications follow from this profile?

If protamine sulfate is treated as a platform-like commodity

• Competitive advantage typically comes from supply chain, labeling clarity, and consistent concentration/packaging.
• Novel differentiation is more plausible in mitigation of hypersensitivity and protocol optimization than in changing the core indication.

If a developer focuses on new clinical value

The most realistic development pathways are:

• Hypersensitivity mitigation protocols (pre-medication regimens, slower infusion procedures, and stratified dosing)
• Pharmacodynamic optimization that reduces under- or over-reversal
• Alternative formulations/sources that improve tolerability without weakening reversal efficacy

---

Key Takeaways

• Protamine sulfate remains a guideline-supported heparin reversal drug with stable clinical demand driven by perioperative heparin exposure. [1-3]
• The clinical pipeline is dominated by perioperative safety and dosing optimization rather than new mechanism entrants.
• Market growth through 2035 is likely to be procedure-volume driven with constrained pricing power due to a multisource environment, producing low-to-mid single-digit CAGR in value in most scenarios.

---

FAQs

1) What is protamine sulfate’s primary clinical use?

It is used to reverse heparin anticoagulation, especially in perioperative settings where rapid reversal is needed. [1-3]

2) What safety risks matter most for protamine sulfate?

Hypersensitivity and acute reactions are the key risks tracked in clinical use and references, including anaphylactoid-type responses. [1-3]

3) Are there meaningful patent-driven brand advantages for protamine sulfate?

Commercial advantage typically depends on supply reliability, dosing consistency, and labeling rather than brand-protectable mechanism innovation, given the established and multisource nature of protamine sulfate use.

4) What drives demand growth more, new patients or procedure volume?

Demand is primarily linked to procedure volume and the share of protocols requiring heparin reversal, not to chronic treatment expansion.

5) What is the most plausible area for incremental R&D differentiation?

Protocol-driven improvements for safety (hypersensitivity mitigation) and pharmacodynamic optimization (reversal kinetics and appropriate dosing) are the most likely differentiators within the clinical utility of protamine sulfate. [1-3]

---

References

[1] Lexicomp. Protamine sulfate: Drug information and indications. Wolters Kluwer.
[2] DailyMed. PROTAMINE SULFATE injection prescribing information. U.S. National Library of Medicine.
[3] British National Formulary (BNF). Protamine sulfate monograph and heparin reversal guidance.